TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Abroad (travel likely)RecruitingPHASE2
Conditions
Colorectal Cancer; Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, Irvine Medical Center, Orange, California, United States
China Medical University Hsinchu Hospital, Hsinchu, Taiwan
Chung Shan Medical University Hospital, Taichung, Taiwan
Study leads
Ray Lee
Study Director
Teclison Limited